• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定 C10orf90 在结肠癌中的致癌新价值,作为临床诊断和预后标志物。

Novel Oncogenic Value of C10orf90 in Colon Cancer Identified as a Clinical Diagnostic and Prognostic Marker.

机构信息

Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Department of Biotechnology, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.

出版信息

Int J Mol Sci. 2024 Sep 29;25(19):10496. doi: 10.3390/ijms251910496.

DOI:10.3390/ijms251910496
PMID:39408824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11476934/
Abstract

C10orf90, a tumor suppressor, can inhibit the occurrence and development of tumors. Therefore, we investigated the gene function of in various tumors using multiple pan-cancer datasets. Pan-cancer analysis results reveal that the expression levels of vary across different tumors and hold significant value in the clinical diagnosis and prognosis of patients with various tumors. In some cancers, the expression level of is correlated with CNV, DNA methylation, immune subtypes, immune cell infiltration, and drug sensitivity in the tumors. In particular, in COAD, the gene is implicated in multiple processes associated with COAD. Cell experiments demonstrate that suppresses the proliferation and migration of colon cancer cells while promoting apoptosis. In summary, plays a role in the onset and progression of various cancers and could potentially serve as an effective diagnostic and prognostic marker for cancer patients. Notably, in COAD, inhibits the proliferation and migration of colon cancer cells, induces apoptosis, and is linked to the advancement of colon cancer.

摘要

C10orf90 是一种肿瘤抑制因子,可以抑制肿瘤的发生和发展。因此,我们使用多个泛癌数据集研究了 C10orf90 在各种肿瘤中的基因功能。泛癌分析结果表明,C10orf90 在不同肿瘤中的表达水平存在差异,对不同肿瘤患者的临床诊断和预后具有重要意义。在某些癌症中,C10orf90 的表达水平与肿瘤的 CNV、DNA 甲基化、免疫亚型、免疫细胞浸润和药物敏感性相关。特别是在 COAD 中,C10orf90 基因与 COAD 相关的多个过程有关。细胞实验表明,C10orf90 抑制结肠癌细胞的增殖和迁移,同时促进细胞凋亡。综上所述,C10orf90 在多种癌症的发生和发展中发挥作用,可能成为癌症患者有效诊断和预后的标志物。值得注意的是,在 COAD 中,C10orf90 抑制结肠癌细胞的增殖和迁移,诱导细胞凋亡,并与结肠癌细胞的进展有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/a35a28766732/ijms-25-10496-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/1a6a09ca43f6/ijms-25-10496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/61e7ee93d057/ijms-25-10496-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/1c07bf62074b/ijms-25-10496-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/9e8dbbf3b76b/ijms-25-10496-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/c99aaa20f2f6/ijms-25-10496-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/55d1f267ff73/ijms-25-10496-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/3fd547a41aef/ijms-25-10496-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/e91435eb4323/ijms-25-10496-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/cfbee1380c96/ijms-25-10496-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/3e8c8ce60369/ijms-25-10496-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/a35a28766732/ijms-25-10496-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/1a6a09ca43f6/ijms-25-10496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/61e7ee93d057/ijms-25-10496-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/1c07bf62074b/ijms-25-10496-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/9e8dbbf3b76b/ijms-25-10496-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/c99aaa20f2f6/ijms-25-10496-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/55d1f267ff73/ijms-25-10496-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/3fd547a41aef/ijms-25-10496-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/e91435eb4323/ijms-25-10496-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/cfbee1380c96/ijms-25-10496-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/3e8c8ce60369/ijms-25-10496-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e09/11476934/a35a28766732/ijms-25-10496-g011.jpg

相似文献

1
Novel Oncogenic Value of C10orf90 in Colon Cancer Identified as a Clinical Diagnostic and Prognostic Marker.鉴定 C10orf90 在结肠癌中的致癌新价值,作为临床诊断和预后标志物。
Int J Mol Sci. 2024 Sep 29;25(19):10496. doi: 10.3390/ijms251910496.
2
Pancancer analysis of NDUFA4L2 with focused role in tumor progression and metastasis of colon adenocarcinoma.NDUFA4L2 在泛癌症中的分析及其在结肠腺癌肿瘤进展和转移中的聚焦作用。
Med Oncol. 2024 Oct 14;41(11):285. doi: 10.1007/s12032-024-02531-1.
3
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.T 盒转录因子 5 的表观遗传失活与结肠癌相关,T 盒转录因子 5 是一种新的肿瘤抑制基因。
Oncogene. 2010 Dec 9;29(49):6464-74. doi: 10.1038/onc.2010.370. Epub 2010 Aug 30.
4
DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma.DEPDC1B:一种与结肠腺癌免疫浸润相关的新型肿瘤抑制基因。
Cancer Med. 2024 Aug;13(15):e70043. doi: 10.1002/cam4.70043.
5
NXPH4 can be used as a biomarker for pan-cancer and promotes colon cancer progression.NXPH4可作为泛癌的生物标志物,并促进结肠癌进展。
Aging (Albany NY). 2024 Apr 12;16(7):5866-5886. doi: 10.18632/aging.205648.
6
LINC00342 regulates cell proliferation, apoptosis, migration and invasion in colon adenocarcinoma via miR-545-5p/MDM2 axis.LINC00342 通过 miR-545-5p/MDM2 轴调控结肠腺癌中的细胞增殖、凋亡、迁移和侵袭。
Gene. 2020 Jun 15;743:144604. doi: 10.1016/j.gene.2020.144604. Epub 2020 Mar 22.
7
SMC4 serves as a potential marker for the diagnosis and prognosis of colon adenocarcinoma.SMC4 可作为结直肠腺癌诊断和预后的潜在标志物。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241286565. doi: 10.1177/03946320241286565.
8
HIG1 domain family member 1A disrupts proliferation, migration, and invasion of colon adenocarcinoma cells.HIG1 结构域家族成员 1A 扰乱结肠腺癌细胞的增殖、迁移和侵袭。
Bioengineered. 2021 Dec;12(2):10501-10511. doi: 10.1080/21655979.2021.1999368.
9
Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.研究与结肠腺癌免疫相关的基因特征,使用 NFM 和 WGCNA 算法预测免疫治疗效果。
Aging (Albany NY). 2024 May 13;16(9):7596-7621. doi: 10.18632/aging.205763.
10
Exploring and validating the necroptotic gene regulation and related lncRNA mechanisms in colon adenocarcinoma based on multi-dimensional data.基于多维数据探索和验证结直肠腺癌中的坏死性基因调控及相关长链非编码 RNA 机制。
Sci Rep. 2024 Sep 27;14(1):22251. doi: 10.1038/s41598-024-73168-3.

本文引用的文献

1
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.中国多中心真实世界研究:BRAF V600E 突变转移性结直肠癌的治疗。
Eur J Surg Oncol. 2023 Nov;49(11):106981. doi: 10.1016/j.ejso.2023.07.007. Epub 2023 Jul 10.
2
IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration.IL-17A 介导的线粒体功能障碍诱导结直肠癌细胞发生细胞焦亡,并促进 CD8+T 细胞浸润肿瘤。
J Transl Med. 2023 May 21;21(1):335. doi: 10.1186/s12967-023-04187-3.
3
Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.
靶向 VPS72 抑制 HCC 进展中的 ACTL6A/MYC 轴活性。
Hepatology. 2023 Nov 1;78(5):1384-1401. doi: 10.1097/HEP.0000000000000268. Epub 2023 Jan 13.
4
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging.癌症免疫治疗影像学的新兴和发展概念。
Radiology. 2023 Jan;306(1):32-46. doi: 10.1148/radiol.210518. Epub 2022 Dec 6.
5
Actin Up: An Overview of the Rac GEF Dock1/Dock180 and Its Role in Cytoskeleton Rearrangement.肌动蛋白激活:Rac GEF Dock1/Dock180 的概述及其在细胞骨架重排中的作用。
Cells. 2022 Nov 11;11(22):3565. doi: 10.3390/cells11223565.
6
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.FDA 批准的小分子蛋白激酶抑制剂的特性:2023 年更新。
Pharmacol Res. 2023 Jan;187:106552. doi: 10.1016/j.phrs.2022.106552. Epub 2022 Nov 17.
7
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.恩考芬尼联合西妥昔单抗治疗既往接受过抗表皮生长因子受体(EGFR)治疗的BRAF V600E突变转移性结直肠癌患者:一项AGEO-GONO病例系列研究
Eur J Cancer. 2022 Jun;168:34-40. doi: 10.1016/j.ejca.2022.03.011. Epub 2022 Apr 15.
8
Should mutant TP53 be targeted for cancer therapy?是否应该针对突变型 TP53 进行癌症治疗?
Cell Death Differ. 2022 May;29(5):911-920. doi: 10.1038/s41418-022-00962-9. Epub 2022 Mar 24.
9
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis.结直肠癌肿瘤微环境及其对肝肺转移的影响。
Cancers (Basel). 2021 Dec 9;13(24):6206. doi: 10.3390/cancers13246206.
10
Loss of fragile site-associated tumor suppressor promotes antitumor immunity via macrophage polarization.脆性部位相关肿瘤抑制因子丢失通过巨噬细胞极化促进抗肿瘤免疫。
Nat Commun. 2021 Jul 14;12(1):4300. doi: 10.1038/s41467-021-24610-x.